NTLA | Intellia Therapeutics Inc
Category: Biotechnology company
Quick infos Headquarters: Cambridge, Massachusetts, United States Trade prices Volume: Market Cap: 4.1B Prev closed: 13.36 Open: 13.87 High: 13.91 Low: 13.37 52 week low: 9.18 52 week high: 19 Dividends: No Dividends Next ER: November 3, 2022 Before Market Opens
About the Company Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and colleagues at University of California. The company has partnerships with Novartis and Regeneron.
Earnings History Date EPS / Forecast Revenue / Forecast March 15, 2023 November 3, 2022 -1.49 / -1.2913.27M / 11.43MBeat! August 4, 2022 -1.33 / -1.314.03M / 9.42MBeat! May 5, 2022 -1.96 / -1.1111.25M / 8.54MBeat! February 24, 2022 -1.09 / -0.94912.85M / 8.26MBeat! view more
Historical Data Date Price Open High Low Vol Change ER Aug 4, 2022 65.43 61.90 65.89
57.63
2.91M -8.74% Aug 3, 2022 71.70 73.00 76.45
70.31
2.84M 11.93% Aug 2, 2022 64.06 62.18 65.09
61.89
661.30K 2.10% Aug 1, 2022 62.74 63.84 65.79
61.94
676.74K -3.12% Jul 29, 2022 64.76 64.99 65.13
63.02
759.29K -1.37% Jul 28, 2022 65.66 67.69 69.34
64.60
613.18K -2.77% Jul 27, 2022 67.53 65.75 67.66
64.36
1.20M 3.34% Jul 26, 2022 65.35 65.36 67.23
63.89
824.13K -0.18% Jul 25, 2022 65.47 64.67 65.54
61.35
596.06K 0.49% Jul 22, 2022 65.15 68.46 68.66
64.22
1.16M -4.47% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company Founded:2014 Employees:104 News
Intellia, Other CRISPR Stocks Hammered On Safety Concerns In New Gene-Editing Test investors.com Jan 25, 2023 4:03 pm
Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat finance.yahoo.com Jan 25, 2023 1:43 pm
Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y finance.yahoo.com Jan 25, 2023 12:18 pm
Intellia (NTLA) Reports Positive Results for CRISPR Candidates finance.yahoo.com Jan 25, 2023 12:15 pm
3 Cathie Wood Stocks to Buy and Hold for 10 Years fool.com Jan 25, 2023 9:23 am Intellia's stock is up 6% on data from an early-stage trial for its Crispr therapy marketwatch.com Jan 25, 2023 8:38 am
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposias Precision Genome Engineering Conference finance.yahoo.com Jan 25, 2023 7:30 am
Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress finance.yahoo.com Jan 25, 2023 7:30 am
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis finance.yahoo.com Jan 25, 2023 7:15 am
Intellia's Hereditary Angioedema Candidate Shows Reduction In Associated Biomarkers, Attack Rates finance.yahoo.com Jan 25, 2023 6:30 am
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought finance.yahoo.com Jan 24, 2023 11:45 am
Intellia Investors Are Dumping Stock on News of Crispr Gene-Editing Success barrons.com Jan 20, 2023 4:37 pm
Intellia Therapeutics Announces Proposed Public Offering of Common Stock finance.yahoo.com Jan 20, 2023 4:37 pm
Intellia Stock Has Tumbled. There Are Issues With Gene-Editing Patents. barrons.com Jan 20, 2023 12:32 pm
Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss finance.yahoo.com Jan 20, 2023 12:20 pm Why Intellia Therapeutics Stock Is Sinking Today fool.com Jan 20, 2023 11:31 am 2 Risky Cathie Wood Growth Stocks to Buy and Hold for 5 Years fool.com Jan 20, 2023 10:15 am
Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies finance.yahoo.com Jan 20, 2023 9:26 am
Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema finance.yahoo.com Jan 11, 2023 7:30 am
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates finance.yahoo.com Jan 25, 2023 8:55 am This company doesn't provide a dividend.
Key Persons CEO : Nessan Bermingham, PhD General Counsel : José Rivera Talk about Intellia Therapeutics Inc below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Consensus
If you want to help pay for server cost or for improving this tool. You can send it via Paypal .
Buy on Amazon In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.
